BioWorld

Jan. 22, 2009

J&J Joins Enabling Technology Effort, Enlight Biosciences

Myriad Snares HIV Drug in $7M Deal with Panacos

Tragara Pays $112M to Jointly Develop S*BIO Compound

Singapore-based S*BIO Pte. Ltd. has joined with San Diego-based Tragara Pharmaceuticals Inc. to develop a potential treatment for blood cancer and possibly solid tumors, in a deal worth up to $112.5 million. (BioWorld Today) Read More

Seattle Genetics Gets SPA to Study Lymphoma Drug

Today's news in brief

BioWorld

BioWorld briefs for Feb. 4, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

BioWorld

Jan. 22, 2009

J&J Joins Enabling Technology Effort, Enlight Biosciences

Myriad Snares HIV Drug in $7M Deal with Panacos

Other News To Note

Clinic Roundup

Appointments And Advancements

Tragara Pays $112M to Jointly Develop S*BIO Compound

Seattle Genetics Gets SPA to Study Lymphoma Drug

Today's news in brief

Today's news in brief

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

MJFF grant supports Bexorg’s translational biomarker work